A time-of-drug-addition approach delineates the timing of early SARS-CoV-2 life cycle steps in A549 cells and validates PF-00835231's early time of action. In a model of the human polarized airway epithelium, PF-00835231 potently inhibits SARS-CoV-2 at low micromolar concentrations. PF-00835231 exhibits the potential as an effective SARS-CoV-2 antiviral.
